Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma.

ABSTRACT: Chimeric antigen receptors (CARs) are among the curative immunotherapeutic approaches that exploit the antigen specificity and cytotoxicity function of potent immune cells against cancers. Neuroblastomas, the most common extracranial pediatric solid tumors with diverse characteristics, could be a promising candidate for using CAR therapies. Several methods harness CAR-modified cells in neuroblastoma to increase therapeutic efficiency, although the assessment has been less successful. Regarding the improvement of CARs, various trials have been launched to overcome insufficient capacity. However, the reasons behind the inadequate response against neuroblastoma of CAR-modified cells are still not well understood. It is essential to update the present state of comprehension of CARs to improve

SUBMITTER: Sawaisorn P 

PROVIDER: S-EPMC7768386 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature